Lifemin (Lisdexamfetamine Dimesylate)

Lisdexamfetamine dimesylate is a central nervous system stimulant used in the management of neurobehavioral disorders.

• Attention deficit hyperactivity disorder (ADHD): Improves concentration, reduces hyperactivity and impulsivity in children, adolescents and adults.
• Binge eating disorder: Decreases the frequency of binge episodes and helps control eating behavior in affected individuals.

• Lisdexamfetamine dimesylate is a pro‑drug that is enzymatically converted to dextroamphetamine after oral absorption. The released dextroamphetamine increases synaptic concentrations of norepinephrine and dopamine by promoting their release and inhibiting reuptake, thereby enhancing neurotransmission in brain regions that regulate attention, impulse control and reward pathways.

Lisdexamfetamine dimesylate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Insomnia: Difficulty falling or staying asleep.
• Decreased appetite: Reduced hunger leading to weight loss.
• Dry mouth: Sensation of oral dryness.
• Headache: Mild to moderate cranial pain.
• Increased heart rate: Palpitations or tachycardia.
• Anxiety: Feelings of nervousness or tension.

Serious or Rare Side Effects

• Cardiovascular events: Chest pain, arrhythmia or sudden cardiac death.
• Psychosis: Hallucinations, delusional thinking or severe agitation.
• Severe hypertension: Markedly elevated blood pressure.
• Seizures: New‑onset or worsening seizure activity.
• Allergic reactions: Rash, itching, swelling or anaphylaxis.
• Prolonged QT interval: Potential for life‑threatening arrhythmias.

Before initiating Lifemin, clinicians should evaluate patient history and monitor ongoing safety parameters.

• Assess cardiovascular status: Check blood pressure and heart rate, especially in patients with pre‑existing heart disease.
• Review psychiatric history: Identify prior psychosis, bipolar disorder or severe anxiety.
• Monitor growth in children: Track height and weight regularly during treatment.
• Evaluate for substance misuse: Consider risk of abuse or dependence.
• Avoid use in uncontrolled hypertension: Defer treatment until blood pressure is stabilized.
• Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture and light.

Lisdexamfetamine dimesylate can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): Risk of hypertensive crisis or serotonin syndrome.
• Other central nervous system stimulants: Additive cardiovascular and CNS stimulation.
• Certain antidepressants (e.g., SSRIs, SNRIs): May increase serotonergic activity and precipitate serotonin syndrome.
• Antihypertensive agents: Potential reduction of blood‑pressure‑lowering effect.
• Acidifying agents (e.g., ascorbic acid): Can increase conversion to active dextroamphetamine, raising exposure.

Moderate Interactions (Monitor Closely)

• Alkalinizing agents (e.g., sodium bicarbonate): May decrease conversion and reduce efficacy.
• Antacids: Can alter absorption rate.
• CYP2D6 inhibitors: May affect metabolic pathways of dextroamphetamine.
• Medications that prolong QT interval: Combined effect may increase arrhythmia risk.
• Herbal supplements (e.g., St. John’s wort): Potential to modify plasma levels.